Document Detail

Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine.
MedLine Citation:
PMID:  22527355     Owner:  NLM     Status:  Publisher    
For practitioners at hospitals seeking to use natural (not genetically modified, as appearing in nature) bacteriophages for treatment of antibiotic-resistant bacterial infections (bacteriophage therapy), Europe's current regulatory framework for medicinal products hinders more than it facilitates. Although many experts consider bacteriophage therapy to be a promising complementary (or alternative) treatment to antibiotic therapy, no bacteriophage-specific framework for documentation exists to date. Decades worth of historical clinical data on bacteriophage therapy (from Eastern Europe, particularly Poland, and the former Soviet republics, particularly Georgia and Russia, as well as from today's 27 EU member states and the US) have not been taken into account by European regulators because these data have not been validated under current Western regulatory standards. Consequently, applicants carrying out standard clinical trials on bacteriophages in Europe are obliged to initiate clinical work from scratch. This paper argues for a reduced documentation threshold for Phase 1 clinical trials of bacteriophages and maintains that bacteriophages should not be categorized as classical medicinal products for at least two reasons: (1) such a categorization is scientifically inappropriate for this specific therapy and (2) such a categorization limits the marketing authorization process to industry, the only stakeholder with sufficient financial resources to prepare a complete dossier for the competent authorities. This paper reflects on the current regulatory framework for medicines in Europe and assesses possible regulatory pathways for the (re-)introduction of bacteriophage therapy in a way that maintains its effectiveness and safety as well as its inherent characteristics of sustainability and in situ self-amplification and limitation.
Gilbert Verbeken; Jean-Paul Pirnay; Daniel De Vos; Serge Jennes; Martin Zizi; Rob Lavigne; Minne Casteels; Isabelle Huys
Related Documents :
23970005 - Compendial activities relating to cold chain management issues: drug products and compo...
24299155 - Medicinal compounds with antiepileptic/anticonvulsant activities.
23195485 - Antimicrobial activities of benzylpenicillin in combination with traditional herbal med...
22395325 - Bleeding risks of herbal, homeopathic, and dietary supplements: a hidden nightmare for ...
11906595 - Work stress: an exploratory study of the practices and perceptions of female junior hea...
24033235 - In the wake of violence: enacting and witnessing hope among people.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-17
Journal Detail:
Title:  Archivum immunologiae et therapiae experimentalis     Volume:  -     ISSN:  1661-4917     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0114365     Medline TA:  Arch Immunol Ther Exp (Warsz)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Laboratory for Molecular and Cellular Technology, Burn Wound Centre, Queen Astrid Military Hospital, Bruynstraat 1, Brussels, Belgium,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Matched Sibling Versus Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Child...
Next Document:  Bone in the belly: traumatic heterotopic mesenteric ossification.